Work

Immunotherapy for Glioblastoma: Adoptive T-cell Strategies

Year: 2018

Type: article

Abstract: Glioblastoma (GBM) is a devastating disease with an extremely poor prognosis. Immunotherapy via adoptive cell transfer (ACT), especially with T cells engineered to express chimeric antigen receptors (CAR), represents a particularly promising approach. Despite the recent success of CAR T cells for blood cancers, the question remains whether this powerful anticancer therapy will ultimately work for brain tumors, and whether the primary immunologic challenges in this disease, which include antigenic heterogeneity, immune suppression, and T-cell exhaustion, can be adequately addressed. Here, we contextualize these concepts by reviewing recent developments in ACT for GBM, with a special focus on pioneering clinical trials of CAR T-cell therapy.

Source: Clinical Cancer Research

DOI: 10.1158/1078-0432.ccr-18-1625

Authors: Bryan D. Choi, Marcela V. Maus, Carl H. June, John H. Sampson

Institutions: Harvard University, Massachusetts General Hospital, University of Pennsylvania, Duke University, Duke Medical Center

Language: English

Topic: Glioma Diagnosis and Treatment

Subfield: Genetics

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: green

Funders: National Institutes of Health, National Cancer Institute, National Institute of Neurological Disorders and Stroke